-
11/22/2023
PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD
-
11/21/2023
PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL
-
10/31/2023
PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS - PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED
-
10/20/2023
PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
-
10/13/2023
Press release: PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
-
09/28/2023
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN
-
08/31/2023
PAION receives UK MHRA approval of Byfavo® (remimazolam) for the induction and maintenance of general anesthesia in adults
-
08/30/2023
PAION AG reports financial results for the First Half-Year 2023
-
08/22/2023
PAION launches Byfavo® (remimazolam) in the first European country for General Anesthesia
-
07/17/2023
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES
-
07/12/2023
PAION AG SUCCESSFULLY HOLDS ITS ANNUAL GENERAL MEETING 2023
-
05/25/2023
PAION IS HOSTING A SPONSORED BYFAVO® SYMPOSIUM AT EUROANAESTHESIA 2023 IN GLASGOW
-
05/17/2023
PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023
-
04/25/2023
POSTPONEMENT OF PUBLICATION OF THE ANNUAL AND CONSOLIDATED FINANCIAL STATEMENTS 2022
-
03/31/2023
PAION AG implements resolved capital reduction
-
03/30/2023
PAION AG reports on fiscal year 2022
-
03/16/2023
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
-
01/25/2023
PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing
-
01/19/2023
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL